Figure 4.

Importance of ICOS for memory-driven asthma. (A–E) ICOS−/−:Rag1−/− (I:R−/−) and Rag1−/− (R−/−) mice were subjected to the Alt-induced memory-driven asthma protocol as per Fig. 1 A. Airway hyperreactivity (A) was measured by flexiVent, two-way ANOVA. Lung eosinophils (CD45+SiglecF+CCR3+ cells; B), ST2+, IL5+, and IL13+ ILC2s (CD45+NK1.1CD25+ICOS+ST2+) cells were measured by FCM (C–E). *, P < 0.01; **, P < 0.001; ***, P < 0.0001, unpaired t test, n = 4/group. (FJ) ICOS−/− and littermate ICOS+/+ mice were subjected to the Alt-induced memory-driven asthma protocol as per Fig. 1 A. Airway hyperreactivity was measured by flexiVent (F). Lung eosinophils, ILCs (LinCD45+CD25+), ILC2s (LinCD45+CD25+PLZF+KLRG1+), and IL13+ ILC2s (CD45+LinCD25+PLZF+KLRG1+) cells were measured by FCM (G–J). *, P < 0.01; **, P < 0.001; ***, P < 0.0001; ns, not significant; two-way ANOVA. (K–P) Comparison of memory (ST2+) and nonmemory (ST2) ILCs between ICOS+/+ and ICOS−/− mice. The frequency of ST2 + ILC2s (K) and KLRG1+ IL13+ and IL5+ ILC2s in ST2+ and ST2 ILCs (L–P). *, P < 0.01; **, P < 0.001; ***, P < 0.0001, unpaired t test, n = 4–5/group. (Q–U) Rag1−/− mice were intranasally pretreated with an anti-ICOSL antibody or an isotype control antibody before recall challenge. Airway hyperreactivity (Q) was measured by flexiVent, two-way ANOVA. Lung eosinophils (CD45+SiglecF+CCR3+ cells; R), ICOS+ST2+ ILCs (CD45+CD25+; S), and IL5+, IL13+ ILC2s (CD45+CD25+ICOS+ST2+; T and U) in the lung digest were measured by FCM. ***, P < 0.001, unpaired t test, n = 4–5/group.

or Create an Account

Close Modal
Close Modal